BRIEF—Sanofi buys into Biomunex antibody technology

Biomunex Pharmaceuticals has entered into a licensing agreement with Sanofi, giving the French pharma giant access to its tech to generate and optimize antibody therapeutics.

Sanofi will take on all R&D, manufacturing and global commercialization activities, and will make an upfront as well as milestone payments, of an undisclosed amount.

Biomunex chief executive Pierre-Emmanuel Gerard said the proceeds, together with money from an upcoming financing round, would fund development of the firm's programs in immuno-oncology and other therapeutic areas.